CN106361740A - Liver protection effect and application of sulforaphen in non-alcoholic fatty liver - Google Patents
Liver protection effect and application of sulforaphen in non-alcoholic fatty liver Download PDFInfo
- Publication number
- CN106361740A CN106361740A CN201610938091.2A CN201610938091A CN106361740A CN 106361740 A CN106361740 A CN 106361740A CN 201610938091 A CN201610938091 A CN 201610938091A CN 106361740 A CN106361740 A CN 106361740A
- Authority
- CN
- China
- Prior art keywords
- sulforaphen
- liver
- preparation
- fatty liver
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a liver protection effect and application of sulforaphen in non-alcoholic fatty liver, and belongs to the fields of biomedicine and food. According to the invention, the sulforaphen can be used for effectively treating liver diseases and decelerating lipid accumulation and steatosis of the liver, has the effect of obviously decelerating non-alcoholic fatty liver, and can reduce the glutamic-pyruvic transaminase and glutamic-oxaloacetic transaminase levels in blood, thereby opening a new way to treat fatty liver diseases and liver function impairment, having important meanings for development of edible and medicinal dual-purpose resources, realizing high-value transformation of active plant resources and promoting fine and deep processing and utilization of agricultural products. The sulforaphen having a liver protection effect can be widely used in the fields of food, medicine and the like, and has obvious social benefits and economic benefits.
Description
Technical field
The present invention relates to the liver protection of sulforaphen and its application in non-alcoholic fatty liver disease, belong to biological
Medicine and field of food.
Background technology
Sulforaphen (Sulforaphane), also known as " Sulforaphane ", in Caulis et Folium Brassicae capitatae, cabbage mustard, the north
In the crucifers such as circle Radix Dauci Sativae, content is abundanter, is common antioxidant, is that the anticancer effect found in vegetable is good
Active substance of plant.Additionally, sulforaphen additionally aids removing Pulmonary bacterial, prevent and treat gout.These research display sulforaphen exist
Prevention and treatment chronic disease aspect has obvious action.
Fatty liver disease refers to that in the hepatocyte that causes due to a variety of causes, athero is excessive, leads to hepatocellular fat
Content increases, and possible cause has the reasons such as excessive drinking, diabetes, the too high, overweight of blood fat.Non-alcoholic fatty liver disease
(non-alcoholic fatty liver disease, nafld) refers to that the other factors in addition to ethanol lead to hepatocyte
The clinical pathology syndrome that steatosis and lipid accumulation are characterized, main cause is had with fat and glucose metabolism disorders etc.
Close.Including pathologic stage such as simple fatty liver (nafl), fat hepatitis (nash), hepatic fibrosis and liver cirrhosis.Mainly disease
Reason physiological performance is hepatic steatosis, inflammatory cell infiltration, abnormal liver function etc..Fatty liver is such as controlled by not in time, meeting
Lead to liver cirrhosis or even hepatocarcinoma.At present, the treatment of non-alcoholic fatty liver disease is except the change of dietary structure and living habit, still
Nothing targetedly Drug therapy.Therefore, find the function of having no toxic side effect and can effectively reduce fatty liver from natural food source
Property composition become fatty liver prevention with treatment focus.
Content of the invention
Based on the problems referred to above, the present invention is found by scientific experimentss, and sulforaphen can be obviously improved the non-of high lipid diet induction
Alcoholic fatty liver, and have no toxic side effect.This new effect, so far there is not yet relevant report.
First purpose of the present invention be provide a kind of suppression or auxiliary treatment or treatment fatty liver disease preparation,
Described preparation is sulforaphen, or described preparation is with sulforaphen as principle active component, or described preparation is with containing Radix Raphani sulfur
The can be used for food or the material of medicine of element are main component.
The preparation of the present invention refers to medicine, food, health food, beverage, enteral nutrition preparation, dietary supplement, veterinary drug
Or feed additive.
In one embodiment of the invention, the non-alcoholic fatty that described fatty liver disease induces for high lipid diet
Liver.
Second object of the present invention is to provide sulforaphen to be used for the purposes that preparation has the preparation of liver protecting effect.
In one embodiment of the invention, described liver protecting effect is the fatty that protection food source sexual factor leads to
Hepatopathy.
In one embodiment of the invention, described liver protecting effect is the fatty that protection food source sexual factor leads to
Hepatopathy.
In one embodiment of the invention, described liver protecting effect refers to suppression or auxiliary treatment or treatment fat
Fat hepatopathy.
In one embodiment of the invention, described fatty liver disease is non-alcoholic fatty liver disease regulating liver-QI function damage.
In one embodiment of the invention, the non-alcoholic fatty that described fatty liver disease induces for high lipid diet
Liver.
Third object of the present invention is to provide a kind of medicine for suppression or auxiliary treatment or treatment fatty liver disease
Compositions, described pharmaceutical composition is with sulforaphen as main active.
In one embodiment of the invention, the fatty liver disease that described fatty liver disease leads to for food source sexual factor.
In one embodiment of the invention, described pharmaceutical composition also includes pharmaceutically acceptable excipient.Institute
State pharmaceutically acceptable excipient and refer to any diluent that can be used for pharmaceutical field, adjuvant and/or carrier.
In one embodiment of the invention, the sulforaphen of the present invention can be applied in combination with other active components, only
They not produce other unfavorable effects, such as anaphylaxiss.
In one embodiment of the invention, the pharmaceutical composition of the present invention can be configured to several dosage form, wherein contains
There are some excipient in pharmaceutical field conventional；For example, oral formulations (such as tablet, capsule, solution or suspension)；Injectable
Preparation (such as injectable solution or suspension, or injectable dried powder, before the injection add water for injection can stand
Use)；Topical formulations (such as ointment or solution).
In one embodiment of the invention, the carrier for pharmaceutical composition of the present invention is available in pharmaceutical field
Common type, comprising: the binding agent of oral formulations, lubricant, disintegrating agent, cosolvent, diluent, stabilizer, suspending agent,
Non-pigment, correctivess etc.；The preservative of injectable formulation, solubilizer, stabilizer etc.；The substrate of topical formulations, diluent,
Lubricant, preservative etc..Pharmaceutical preparation can by oral administration or parenteral (such as intravenouss, subcutaneous, intraperitoneal or local)
Administration, if some drugses are unstable under the conditions of stomach, can be configured to enteric coated tablets.
In one embodiment of the invention, described sulforaphen dosage is daily 10-150mg/kg body weight.
In one embodiment of the invention, described pharmaceutical composition and label are put together；Record on described label
There is the information that sulforaphen dosage is daily 10-150mg/kg body weight.
Fourth object of the present invention is to provide a kind of ppar γ that high lipid diet can be suppressed to induce and fas expression to carry
High preparation, described preparation is with sulforaphen as principle active component.
5th purpose of the present invention is to provide a kind of preparation of the hepatocyte inflammatory reaction of suppression high lipid diet induction, institute
State preparation with sulforaphen as principle active component.
In one embodiment of the invention, described hepatocyte inflammatory reaction refers to the change of p-p38 phosphorylation level
Hepatocyte inflammatory reaction.
Beneficial effects of the present invention:
The present invention proposes sulforaphen and can be used for preparing the purposes of the medicine for the treatment of hepatopathy, and described hepatopathy includes fat
Property hepatopathy and liver dysfunction, described fatty liver disease includes the fatty liver disease that food-borne and hereditary factors lead to, especially
Refer to non-alcoholic fatty liver disease.According to the present invention, sulforaphen can be used for effectively treating hepatopathy, slow down liver lipids pile up and
Steatosis, significantly slow effect it is possible to reduce glutamate pyruvate transaminase and millet straw in blood to turn ammonia to non-alcoholic fatty liver disease
The level of enzyme, thus opening new road for treating fatty liver disease and liver dysfunction, the exploitation to medicine-food two-purpose resource
Significant, and achieve the high level conversion of active plant resource, the intensive processing promoting agricultural product utilizes.Described
There is the sulforaphen of the liver protecting effect, can be widely applied to food and medicine and other fields, there is significant social benefit and warp
Ji benefit.
Brief description
After Fig. 1 is feeding sulforaphen, the variation diagram of Mouse Weight；
After Fig. 2 is feeding sulforaphen, the variation diagram of mouse liver weight regulating liver-QI body ratio；
After Fig. 3 is feeding sulforaphen, the variation diagram of mouse epididymis fat pad weight and fat body ratio；
After Fig. 4 is feeding sulforaphen, the variation diagram of mice food-intake；
After Fig. 5 is feeding sulforaphen, the variation diagram of mouse liver tissue morphology；
After Fig. 6 is feeding sulforaphen, the content of glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, GOT and alkali phosphatase in mouse blood
Variation diagram；
After Fig. 7 is feeding sulforaphen, triglyceride, T-CHOL, low density lipoprotein, LDL, high density fat in mouse blood
The changes of contents figure of albumen；
After Fig. 8 is feeding sulforaphen, light microscopic figure after the liver paraffin section of mice and he dyeing；
After Fig. 9 is feeding sulforaphen, light microscopic figure after the liver frozen section of mice and oil red dyeing；
After Figure 10 is feeding sulforaphen, the protein expression situation of ppar γ, fas, p-p38, p-erk in liver cell.
Specific embodiment
To illustrate the present invention with reference to embodiment.
Following examples are merely to illustrate the present invention rather than limit the scope of the invention.Unreceipted concrete bar in embodiment
The experimental technique of part, generally according to normal condition, the such as condition described in " Molecular Cloning:A Laboratory guide ", or according to maker
Condition proposed by business.
The nonalcoholic fatty liver model Mus that inventor induces first with food-borne, i.e. high lipid food (fat mass ratio
For 24%) induce c57bl/6j mice 12 weeks, induce it to produce fatty liver.Find that the nursing of high lipid food can by experiment detection
To lead to the athero degeneration of mouse liver.
The foundation of non-alcoholic fatty liver disease mouse model and packet
Choose 8 week old male c57bl/6j mices, (steady temperature 22-24 DEG C, constant humidity 50- under experimental situation
60%) normal feedstuff adaptability is fed one week, free water.After one week, it is randomly divided into 2 groups: chow diet group (9), experiment
Group (30).After 12 weeks, in experimental group, 18 body weight of random choose are more than or equal to the mice of 40g, are arbitrarily divided into 2 groups: high fat
Feedstuff group (9), sulforaphen group (9).In addition to chow diet group feeding normal diet, remaining 2 groups equal feeding high lipid foods,
In sulforaphen group, sulforaphen is added in high lipid food, and addition is the 0.1-2% of feeding quality.Monitor weekly the body of mice
Weight and food-intake, to understand the function of alleviating athero, observe its change for mice physical signs, record is different simultaneously
Body weight and every physical signs.
Mouse Weight, feed measuring method: measured with electronic balance, calculating difference.
Obesity mice body weight and the action effect of major lipids metabolic organ that embodiment 1 sulforaphen induces to high fat
Fig. 1 is the variation diagram of Mouse Weight after sulforaphen is processed, and ns represents that both compare and do not have significant difference, permissible
Think both approximately equals.In 6 weeks, Mouse Weight does not substantially become Fig. 1 a display feeding sulforaphen compared with high lipid diet group weekly
Change, after 6 weeks, Mouse Weight slightly reduces Fig. 1 b display feeding sulforaphen, but does not have significance,statistical poor compared with high lipid diet group
Different.Fig. 2 display liver weight regulating liver-QI body ratio does not have significant change；Fig. 3 display weight of epididymal fat pad and fat body ratio be not obvious
Change.Process the obesity mice of high lipid diet induction as can be seen here with sulforaphen, the body weight of obesity mice can not be reduced, inspection
Survey and find that the liver of mice and the weight of epididymal adipose tissues pad all do not change significantly, illustrate that sulforaphen can not suppress fat
Produce, do not reduce an accumulation of body fat, promote the effect of weight reducing that body weight reduces.
The action effect of the obesity mice food-intake that embodiment 2 sulforaphen induces to high fat
After Fig. 4 is feeding sulforaphen, the variation diagram of mice food-intake.There it can be seen that the 6 of feeding sulforaphen weeks
In, sulforaphen group more more than the mice food-intake of high lipid food group although this gap very little, but the mistake due to two groups of data
Difference very little, still has statistics pole significant difference.Sulforaphen can promote the appetite of mice as can be seen here, increases entering of mice
Appetite, in conjunction with the variation diagram of Fig. 1 Mouse Weight, it is more to obtain sulforaphen group mice food-intake, but body weight higher fat group has
Downward trend.
The action effect of the obesity mice liver morphology that embodiment 3 sulforaphen induces to high fat
Fig. 5 be sulforaphen process mice after tissue form it can be seen that sulforaphen process after mice liver edge
Relatively thin, there is no the swelling phenomenon that generation model group is similar to.Liver color is more normal, and liver surface does not have greasy feeling.Although Radix Raphani
The Mouse Weight higher fat group that thionin is processed does not have significant change, but the state of corresponding fatty liver has been alleviated.
The action effect of the obesity mice liver function that embodiment 4 sulforaphen induces to high fat
Glutamate pyruvate transaminase (alt) is primarily present in liver, heart and skeletal muscle, when hepatocyte or some tissue injurys or
Necrosis, all can make the glutamate pyruvate transaminase in blood raise.Glutamic oxaloacetic transaminase, GOT (ast) is the finger of liver function test on clinical medicine
Mark, for judging whether liver suffers damage.During liver cell lesion, ast is released into blood, therefore serum ast activity is damaged with hepatocyte
The degree of evil increases.Alkali phosphatase (alp) is mainly used in obstructive jaundice, primary hepatocarcinoma, secondary liver cancer, cholestasis
The inspection of property hepatitis etc..When suffering from these diseases, hepatocyte excessively manufactures alp, enters blood through lymphatic channel and sinus hepaticus, simultaneously because
Biliary tract bile excretion obstacle in liver, reflux enters blood and causes serum alkaline phosphatase significantly raised.Fig. 6 is that sulforaphen process is little
The change of glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, GOT and alkaline phosphatase levels in serum after Mus.After result display sulforaphen is processed,
Reduce alt the and ast level of mice, the damage to liver function for the Fat Accumulation in the effective antagonism liver of sulforaphen energy is described
Wound.Fatty liver hepatopathy can cause the damage reason of liver to be that the triglyceride spending increase can cause various inflammation to occur more, enters
And act on hepatic parenchymal cellses and cause hepatocellular necrosis thus damaging liver function.Sulforaphen can effectively reduce internal glycerol
The content of three esters, enters the inflammatory reaction that guild reduces liver, promotes the damage of liver function.And then sulforaphen can be used as passing through
The accumulation adjusting lipid is protected to the liver of human body, reaches the effect of hepatoprotective.
The action effect of the obesity mice blood lipids index that embodiment 5 sulforaphen induces to high fat
Fig. 7 is that sulforaphen processes after mice triglyceride, T-CHOL, low density lipoprotein, LDL, high density in mice serum
The change of lipoprotein levels.After sulforaphen is processed, T-CHOL, low density lipoprotein, LDL and high density lipoprotein in mice serum
Level declines compared with high lipid food group.
The effect of the obesity mice pathology of livers that embodiment 6 sulforaphen induces to high fat
Fig. 8 is light microscopic figure after the paraffin section of mouse liver after sulforaphen process and he dyeing.After high fat induction, mice
Liver cell volume becomes big, and with the appearance of fat vacuole, blister sample degeneration and steatosis in most cells, with medium and small
Based on type cavity, simultaneously with the infiltration of inflammatory cell.After sulforaphen is processed, the big alveolitoid steatosis of liver have significantly
Alleviate, the blister sample of liver cell becomes and the degree of steatosis substantially mitigates, and the number of fat vacuole significantly reduces, present few
Number calcium, reduces the liver lipids degeneration that high fat induction produces.Sulforaphen can effectively suppress liver inner lipid to amass
Tired, alleviate the steatosis in liver, can effectively, specificity reduce individuality internal organs Fat Accumulation, predictable
Reduce the probability of happening that patient produces cardiovascular disease.
Wherein, the preparation of paraffin section and he dyeing:
Take hepatic tissue appropriate, fix 24h with 4% paraformaldehyde, flowing water rinses a few hours, ethanol dehydration step by step, diformazan
Benzene is transparent, waxdip, paraffin embedding, section, and thickness is 6 μm.60 DEG C of baking oven 30min are put in section melt to wax, through dimethylbenzene
, dewax each 5min, rehydration in graded ethanol.After brazilwood extract dyeing 8s, flowing water rinses about 15min.With 1% hydrochloric acid second
After alcohol liquid flooding indigo plant 7s, flowing water rinses about 15min.With 0.5% Yihong ethanol counterstaining.With gradient concentration ethanol dehydration extremely
100% ethanol, through dimethylbenzene, dewax each 3-5min, finally uses neutral gum mounting.
The effect of the obesity mice liver cell fat drips accumulation that embodiment 7 sulforaphen induces to high fat
The present invention is verified to the accumulation of mouse liver fat drop using the method for oil red dyeing after frozen section.
After Fig. 9 is for sulforaphen process, light microscopic figure after the frozen section of mouse liver and oil red dyeing.After can see that sulforaphen is processed
Mouse liver cell in fat drop number be considerably less than high fat group mice, the process of surface sulforaphen can reduce liver
The accumulation of middle fat, in its liver cell, the number of fat drop and volume are significantly less than high fat group mice.
Wherein, the preparation of frozen section and oil red dyeing:
The same area testing Hepar Mus in each group takes appropriate tissue, and paraformaldehyde fixes 2h, 30% sucrose dehydration 8-12h,
Oct embeds.It is placed on -70 DEG C of Refrigerator stores.Freezing microtome is cut into slices, and slice thickness is 10 μm.Frozen section room temperature is slightly dry, and 60%
Ethanol is slightly washed, and contaminates and dyes (60% oil red o stock solution adds 40%, and list steams water) 10-15min in oil red o dye liquor working solution, and 60%
Ethanol breaks up, washing, and hematoxylin contaminates core 1min, washes 1min, suck dry moisture, glycerol mounting.
Lipogenesis related gene protein expression water in the obesity mice liver that embodiment 8 sulforaphen induces to high fat
Flat effect
The present invention adopts the method for protein immunoblotting (western blotting) to lipid metabolism controlling gene
Ppar γ, fas and mapk signal path is verified.Figure 10 is ppar γ, fas that sulforaphen processes liver organization after mice
Expression and the change of mapk phosphorylation.As seen from the figure, after feeding high lipid food, the lipid metabolism regulation and control of mouse liver
The expression of gene ppar γ and fas has all risen, and after sulforaphen is processed, ppar γ and fas expression have decline.High
The phosphorylation level of p-erk, p-p38 of fat group rises compared with chow diet group, after sulforaphen is processed, both phosphorylation levels
Decline.Show that sulforaphen can lower the generation of the synthesis suppression triglyceride of ppar γ and fas, lower p-p38 phosphoric acid simultaneously
Change level suppresses the generation of hepatocyte inflammatory reaction.
Wherein, protein immunoblotting (western blotting):
Select 3 murine liver tissue for every group, add lysate, ultrasonication, after cooled on ice, 12000rpm is centrifuged
15min, upper strata is fat, takes off a layer supernatant liquid, -20 save backup.Carry out sds-page gel electrophoresiss, transferring film, close, one
Anti- overnight recovery one resists, and tbst rinses 3 times, two anti-room temperatures 2h, tbst rinsing 3 times, development.
To sum up, according to the present invention, sulforaphen can suppress the long-pending of fat drips in the mouse liver cell of high lipid diet induction
Tired, it has remarkable effect for the alleviation of non-alcoholic fatty liver disease, can effectively prevent and/or treat non-alcoholic fatty liver disease.But
It is the effect that blood fat situation is not produced with improvement.Meanwhile, after sulforaphen is processed, the body weight higher fat group of mice has decline, but
There is no significant difference, and liver function indexes alt and ast has obvious downward, illustrate that sulforaphen can protect fat initiation
Compromised liver function, reaches the effect of hepatoprotective.And these phenomenons may with lipid metabolism controlling gene ppar γ, fas and
The downward of mapk signal path is relevant, and wherein deeper mechanism of action also needs to further verify and inquire into.The present invention
A kind of sulforaphen with liver-protecting function is provided, and assesses its inhibition to fatty liver, thus to medicine-food two-purpose resource
Exploitation provides theoretical foundation.And sulforaphen to the effect of other complication in addition it is also necessary to be verified further.
Although the present invention is open as above with preferred embodiment, it is not limited to the present invention, any is familiar with this skill
The people of art, without departing from the spirit and scope of the present invention, can do various changes and modification, therefore the protection model of the present invention
Enclosing should be by being defined that claims are defined.
Claims (10)
1. a kind of suppression or auxiliary treatment or treatment fatty liver disease preparation it is characterised in that described preparation be Radix Raphani sulfur
Element, or described preparation is with sulforaphen as principle active component, or described preparation is can be used for food containing sulforaphen
Or the material of medicine is main component.
2. preparation according to claim 1 it is characterised in that described preparation refer to medicine, food, health food, beverage,
Enteral nutrition preparation, dietary supplement, veterinary drug or feed additive.
3. preparation according to claim 1 is it is characterised in that the non-ethanol that induces for high lipid diet of described fatty liver disease
Property fatty liver.
4. sulforaphen is used for the purposes that preparation has the preparation of liver protecting effect.
5. purposes according to claim 4 is it is characterised in that described liver protecting effect is to protect food source sexual factor to lead to
Fatty liver disease.
6. a kind of pharmaceutical composition for suppression or auxiliary treatment or treatment fatty liver disease, described pharmaceutical composition is with trailing plants
Fore-telling thionin is main active.
7. pharmaceutical composition according to claim 6 is it is characterised in that described pharmaceutical composition also includes pharmaceutically can connecing
The excipient being subject to；Described pharmaceutically acceptable excipient refer to any diluent that can be used for pharmaceutical field, adjuvant and/or
Carrier.
8. pharmaceutical composition according to claim 6 is it is characterised in that described pharmaceutical composition and label are put together；
The information that sulforaphen dosage is daily 10-150mg/kg body weight is recorded on described label.
9. a kind of can suppress the ppar γ of high lipid diet induction and preparation that fas expression improves is it is characterised in that described system
Agent is with sulforaphen as principle active component.
10. a kind of preparation of the hepatocyte inflammatory reaction of suppression high lipid diet induction is it is characterised in that described preparation is with Radix Raphani sulfur
Element is principle active component.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610938091.2A CN106361740A (en) | 2016-10-25 | 2016-10-25 | Liver protection effect and application of sulforaphen in non-alcoholic fatty liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610938091.2A CN106361740A (en) | 2016-10-25 | 2016-10-25 | Liver protection effect and application of sulforaphen in non-alcoholic fatty liver |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106361740A true CN106361740A (en) | 2017-02-01 |
Family
ID=57896571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610938091.2A Pending CN106361740A (en) | 2016-10-25 | 2016-10-25 | Liver protection effect and application of sulforaphen in non-alcoholic fatty liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106361740A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108743576A (en) * | 2018-08-31 | 2018-11-06 | 大连医科大学 | Application of the sulforaphen in preparing the food, health products or drug for preventing diabetic keratopathy lesion |
| CN111012773A (en) * | 2019-12-09 | 2020-04-17 | 浙江工业大学 | New application of sulforaphane and pharmaceutical composition containing sulforaphane |
| CN113262218A (en) * | 2020-02-14 | 2021-08-17 | 无锡杰西医药股份有限公司 | Application of isothiocyanate compounds |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104968342A (en) * | 2012-11-19 | 2015-10-07 | 安德斯·罗森格伦 | Sulforaphane for treating or reducing insulin resistance of the liver |
| KR20150131476A (en) * | 2014-05-15 | 2015-11-25 | 가톨릭대학교 산학협력단 | Composition comprising sulforaphane derivatives as active ingredient for preventing and treating hepatic disease |
-
2016
- 2016-10-25 CN CN201610938091.2A patent/CN106361740A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104968342A (en) * | 2012-11-19 | 2015-10-07 | 安德斯·罗森格伦 | Sulforaphane for treating or reducing insulin resistance of the liver |
| KR20150131476A (en) * | 2014-05-15 | 2015-11-25 | 가톨릭대학교 산학협력단 | Composition comprising sulforaphane derivatives as active ingredient for preventing and treating hepatic disease |
Non-Patent Citations (3)
| Title |
|---|
| GABSIK YANG等: "A pharmacological inhibitor of NLRP3 infammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet", 《SCIENTIFIC REPORTS》 * |
| 付建飞等: "莱菔硫烷对代谢性疾病的调控作用研究进展", 《中国药理学与毒理学杂志》 * |
| 张慧琴: "莱菔硫烷对脂肪细胞的代谢调控作用及分子机制研究", 《宁波大学硕士学位论文》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108743576A (en) * | 2018-08-31 | 2018-11-06 | 大连医科大学 | Application of the sulforaphen in preparing the food, health products or drug for preventing diabetic keratopathy lesion |
| CN111012773A (en) * | 2019-12-09 | 2020-04-17 | 浙江工业大学 | New application of sulforaphane and pharmaceutical composition containing sulforaphane |
| CN113262218A (en) * | 2020-02-14 | 2021-08-17 | 无锡杰西医药股份有限公司 | Application of isothiocyanate compounds |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Barrett et al. | A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris): a review of clinical studies on weight loss and glycemic control | |
| Sundaram et al. | Modulatory effect of green tea extract on hepatic key enzymes of glucose metabolism in streptozotocin and high fat diet induced diabetic rats | |
| Gadang et al. | Dietary bitter melon seed increases peroxisome proliferator-activated receptor-γ gene expression in adipose tissue, down-regulates the nuclear factor-κB expression, and alleviates the symptoms associated with metabolic syndrome | |
| Li et al. | A-type procyanidins from litchi pericarp ameliorate hyperglycaemia by regulating hepatic and muscle glucose metabolism in streptozotocin (STZ)-induced diabetic mice fed with high fat diet | |
| Xia et al. | Anti-obesity and hypolipidemic effects of ethanolic extract from Alpinia officinarum Hance (Zingiberaceae) in rats fed high-fat diet | |
| Fiaccadori et al. | Nutritional evaluation and management of AKI patients | |
| KR20080105470A (en) | Food composition containing ginseng fruit extract for preventing and improving obesity | |
| Murugesan et al. | Naringenin increases insulin sensitivity and metabolic rate: A case study | |
| CN106361740A (en) | Liver protection effect and application of sulforaphen in non-alcoholic fatty liver | |
| CN113546097B (en) | Application of ethanol extract of cordyceps guangdongensis fruiting body in preparation of medicine for preventing obesity and hyperlipidemia | |
| JP2008174539A (en) | Healthy and functional food for obesity patient using purple-colored potato | |
| Lee et al. | Hypoglycemic and antioxidant effects of Daraesoon (Actinidia arguta shoot) in animal models of diabetes mellitus | |
| He et al. | New understanding of Angelica sinensis polysaccharide improving fatty liver: The dual inhibition of lipid synthesis and CD36-mediated lipid uptake and the regulation of alcohol metabolism | |
| WO2020087784A1 (en) | Sunflower head-job's tears seed compound composition and use thereof in preparing drugs for treating liver damage | |
| WO2017000902A1 (en) | Use of zoledronic acid to prepare drug treating fatty liver disease | |
| CN114632101B (en) | Cordyceps guangdongensis weight-losing lipid-lowering liver-protecting compound and preparation method and application thereof | |
| Piña-Contreras et al. | Raspberry (Rubus idaeus L.), a promising alternative in the treatment of hyperglycemia and dyslipidemias | |
| CN105558198A (en) | Health-care tea capable of reducing blood sugar and preparation method of health-care tea | |
| He et al. | Network pharmacology unveils spleen-fortifying effect of Codonopsis Radix on different gastric diseases based on theory of “same treatment for different diseases” in traditional Chinese medicine | |
| CN107823286A (en) | Potentilla viscosa Donn extract and its application | |
| CN103690821A (en) | Composition for assisting in reducing blood fat | |
| CN114432337A (en) | Application of cordyceps guangdongensis fruiting body polysaccharide in preparation of medicine for treating and improving obesity and related diseases | |
| Mansour et al. | What are the main areas of focus to prevent or treat non‐alcoholic fatty liver disease? | |
| KR101336068B1 (en) | Anti-diabetes composition comprising oriental herbal extracts and fractions | |
| CN110420270A (en) | A kind of functional composition containing camellia oil and fish oil and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170201 |
|
| RJ01 | Rejection of invention patent application after publication |